These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 34364546)
1. Sodium hyaluronate-g-2-((N-(6-aminohexyl)-4-methoxyphenyl)sulfonamido)-N-hydroxyacetamide with enhanced affinity towards MMP12 catalytic domain to be used as visco-supplement with increased degradation resistance. Leone G; Pepi S; Consumi M; Lamponi S; Fragai M; Martinucci M; Baldoneschi V; Francesconi O; Nativi C; Magnani A Carbohydr Polym; 2021 Nov; 271():118452. PubMed ID: 34364546 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Nuti E; Casalini F; Santamaria S; Gabelloni P; Bendinelli S; Da Pozzo E; Costa B; Marinelli L; La Pietra V; Novellino E; Margarida Bernardo M; Fridman R; Da Settimo F; Martini C; Rossello A Eur J Med Chem; 2011 Jul; 46(7):2617-29. PubMed ID: 21514700 [TBL] [Abstract][Full Text] [Related]
3. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024 [TBL] [Abstract][Full Text] [Related]
9. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids. Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268 [TBL] [Abstract][Full Text] [Related]
10. Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases. Krumme D; Tschesche H Bioorg Med Chem Lett; 2002 Mar; 12(6):933-6. PubMed ID: 11958997 [TBL] [Abstract][Full Text] [Related]
11. The synthesis and biological activity of a novel series of diazepine MMP inhibitors. Levin JI; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Skotnicki JS; Albright JD Bioorg Med Chem Lett; 1998 Oct; 8(19):2657-62. PubMed ID: 9873598 [TBL] [Abstract][Full Text] [Related]
12. Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. Feng Y; Likos JJ; Zhu L; Woodward H; Munie G; McDonald JJ; Stevens AM; Howard CP; De Crescenzo GA; Welsch D; Shieh HS; Stallings WC Biochim Biophys Acta; 2002 Jul; 1598(1-2):10-23. PubMed ID: 12147339 [TBL] [Abstract][Full Text] [Related]
13. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871 [TBL] [Abstract][Full Text] [Related]
14. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Levin JI; Du MT; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Moy FJ; Powers R; Jin G; Cowling R; Skotnicki JS Bioorg Med Chem Lett; 2001 Jan; 11(2):235-8. PubMed ID: 11206467 [TBL] [Abstract][Full Text] [Related]
15. An integrated structure- and pharmacophore-based MMP-12 virtual screening. Ramezani M; Shamsara J Mol Divers; 2018 May; 22(2):383-395. PubMed ID: 29423648 [TBL] [Abstract][Full Text] [Related]
16. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays. Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283 [TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid alkyl derivative: A novel inhibitor of metalloproteases and hyaluronidases. Pavan M; Galesso D; Secchieri C; Guarise C Int J Biol Macromol; 2016 Mar; 84():221-6. PubMed ID: 26709144 [TBL] [Abstract][Full Text] [Related]
18. An injectable, self-healing and MMP-inhibiting hyaluronic acid gel via iron coordination. Gao Z; Yang X; Jones E; Bingham PA; Scrimshire A; Thornton PD; Tronci G Int J Biol Macromol; 2020 Dec; 165(Pt B):2022-2029. PubMed ID: 33080264 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases. Faust A; Waschkau B; Waldeck J; Höltke C; Breyholz HJ; Wagner S; Kopka K; Schober O; Heindel W; Schäfers M; Bremer C Bioconjug Chem; 2009 May; 20(5):904-12. PubMed ID: 19374404 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Gabelloni P; Da Pozzo E; Bendinelli S; Costa B; Nuti E; Casalini F; Orlandini E; Da Settimo F; Rossello A; Martini C Neuroscience; 2010 Jun; 168(2):514-22. PubMed ID: 20382206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]